Key Takeaways
AstraZeneca Plc received a double dose of good news from European regulators, with a key panel recommending the approval of two major cancer therapies, including one that had faced a recent setback in the U.S.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Enhertu, co-developed with Daiichi Sankyo, to treat a wide range of solid tumors expressing the HER2 protein. The committee also backed AstraZeneca's experimental breast cancer pill, camizestrant.
The recommendation for camizestrant is particularly significant. It comes just weeks after an advisory panel to the U.S. Food and Drug Administration voted against the drug, citing concerns over the design of a pivotal late-stage trial. The positive European view may help allay investor concerns and paves the way for approval in the EU for use in combination with a CDK4/6 inhibitor.
"The recommendation is an important first step and we will work with different countries for access after approval," said Susan Galbraith, a senior executive at AstraZeneca. The company projects the drug could achieve peak annual sales of more than $5 billion and is one of 20 new medicines it hopes to launch by 2030 to meet an $80 billion revenue target.
The CHMP's positive opinion on camizestrant was based on a late-stage study where the drug, combined with other cancer medicines, reduced the risk of cancer progression or death by 56%. The trial showed the combination therapy controlled the disease for an average of about 16 months, compared to just over nine months with standard treatment.
For Enhertu, the CHMP recommendation covers its use in adults with HER2-positive metastatic solid tumors. This tumor-agnostic approval, based on the tumor's genetic profile rather than its location in the body, opens up a significant new market for the blockbuster drug.
The positive CHMP opinions de-risk the path to final European Commission approval, which typically follows the committee's recommendations within a few months. This is likely to boost investor confidence in both AstraZeneca and its partner Daiichi Sankyo, as analysts revise future earnings forecasts based on expanded market access for these key oncology assets. Investors will now be closely watching for further updates on discussions with the FDA regarding camizestrant.
This article is for informational purposes only and does not constitute investment advice.
